Investors Face August Deadline in GeneDx Securities Class Action

The lawsuit, filed as Basma v. GeneDx Holdings Corp. in the U.S. District Court for the District of Connecticut, alleges that executives violated the Securities Exchange Act of 1934. The core of the complaint centers on the April 2025 acquisition of Fabric Genomics, an AI-driven firm. Plaintiffs claim that GeneDx failed to disclose critical operational issues within the newly acquired unit, which ultimately weighed on the company’s financial health.

The impact of these undisclosed issues surfaced on May 4, 2026, when GeneDx reported its first-quarter results. The company disclosed a decline in adjusted gross margins from 74% to 69% and a significant $31.3 million impairment loss linked to Fabric Genomics. Furthermore, GeneDx lowered its projected earnings guidance from a range of $540–$555 million to $475–$490 million. Following the announcement, the company's stock price plummeted by over 49%.

Under the Private Securities Litigation Reform Act of 1995, those with the largest financial losses during the specified period are encouraged to apply for the lead plaintiff role. While the lead plaintiff directs the litigation and chooses legal counsel, individual investors remain eligible to participate in any potential settlement regardless of whether they serve in a representative capacity.